Abstract
Zoletorv, a new fixed-combination hypolipidaemic drug combin ing a modern and effective statin (atorvastatin) with a selective cholesterol absorption inhibitor (ezetimibe), has been marketed in the Czech Republic since September 2016. This fixed combination of two groups of hypolipidaemic drugs is more effective than statin monotherapy (dual inhibition principle).
The IMPROVE-IT study has shown that the statin-ezetimibe combination significantly reduces the cardiovascular risk while being very well tolerated. The fixed combination of active substances contributes to an improved compliance with treatment. (C) 2017, Ambit Media a.s.
All rights reserved.